Resistance to metronidazole (MTZ) in Helicobacter pylori is associated with mutations in rdxA, encoding an oxygen-insensitive NADPH nitroreductase, and mutations in frxA, encoding a NAD(P)H-flavin oxidoreductase. Despite this association, the strict correlation of MTZ resistance with mutations in rdxA or frxA is still controversial. In this study, rdxA allelic replacement was used to distinguish resistance-associated nucleotide mutations from the natural genetic diversity of H. pylori. Replacement with truncated rdxA resulted in MTZ resistance, whereas replacement with missense-mutated rdxA from resistant clinical isolates failed to yield MTZ resistance. Thus, although truncation of rdxA confers MTZ resistance in G27 H. pylori, MTZ resistance found in other clinical isolates is not due to the identified amino-acid substitutions. Three of our MTZ-resistant clinical isolates expressed functional rdxA and two of these also encoded full-length frxA. Therefore, MTZ resistance can arise in H. pylori possessing functional rdxA, suggesting that other factors are involved in MTZ resistance.
INTRODUCTION
Since Helicobacter pylori was discovered in human gastric biopsy specimens in 1982, 1 it has been recognized as a significant contributing factor to the development of a number of gastric disorders. These include gastritis, ulcer disease and two distinct forms of gastric cancer, gastric adenocarcinoma and B-cell-mucosa-associated lymphoma. [2] [3] [4] [5] [6] H. pylori chronically infects more than 50% of the world's population, making it one of the most common bacterial infections worldwide. Given the large number of infected individuals and the strong association of H. pylori infection with gastric disease, H. pylori exerts a tremendous medical burden. This fact makes effective treatment regimens extremely important.
Metronidazole (MTZ), a synthetic nitroimidazole, was a critical ingredient of the first successful H. pylori therapy and remains a major component of several multidrug therapies that contain a proton pump inhibitor and a combination of two or more antibiotics (MTZ, clarithromycin, amoxicillin or tetracycline). 7, 8 A major obstruction to successful H. pylori treatment is the presence of antibiotic-resistant strains. In fact, resistance to MTZ is common among clinically isolated H. pylori, with frequencies ranging from 10% to more than 90%, depending on the geographic region and patient group. 9 ,10 MTZ resistance is of clinical significance because it decreases the effectiveness of popular and affordable MTZ-containing anti-H. pylori therapies. 11, 12 In addition, as MTZ is also used against a wide variety of prokaryotic and eukaryotic pathogens, [13] [14] [15] understanding the whole range of MTZ resistance mechanisms utilized by H. pylori may shed light on similar pathways in other clinically significant microbes.
The mechanism of antimicrobial action of MTZ has been investigated in anaerobic microbes. 13, 16, 17 The cytotoxicity of MTZ is due to unstable intermediates that damage the DNA, resulting in strand breakage, helix destabilization, unwinding and ultimately cell death. 18, 19 Moreover, the anti-microbial action of MTZ is dependent on its reductive activation by the redox system of the target cell. 20 This study focuses on the mechanisms of susceptibility and resistance of H. pylori to MTZ. In this bacterium, MTZ resistance has been shown to be strongly associated with mutations in rdxA, a chromosomal gene encoding an oxygen-insensitive NADPH nitroreductase, and mutations in frxA, a chromosomal gene encoding a NAD(P)H-flavin oxidoreductase. However, the absolute association of H. pylori MTZ resistance with mutations of rdxA or frxA is still a debated topic. [21] [22] [23] To conclusively prove this association, the contribution of specific rdxA or frxA mutations to MTZ resistance needs to be confirmed using classical genetic techniques. However, genetic tools and strategies for manipulation of H. pylori still lag behind those available for other model organisms. In this study, both rdxA and frxA genes from clinically isolated H. pylori strains were analyzed for sequence variation. To determine whether specific identified mutations in rdxA were responsible for the resistance patterns associated with the clinical isolates, allelic exchange was used to replace the rdxA gene of an MTZ-sensitive wild-type H. pylori strain with the rdxA gene from most of the clinical isolates. Minimum inhibitory concentrations (MICs) of MTZ of these rdxA-replaced transformants were then determined to evaluate the contribution of the rdxA mutations to MTZ resistance.
MATERIALS AND METHODS
H. pylori strains and culture condition A total of 10 clinical H. pylori isolates, five MTZ-sensitive (S1-S5) and five MTZ-resistant (R1-R5), were obtained from patients at the Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. A written informed consent was received from each patient. The Institutional Review Board of Human Research at the Catholic University of Korea approved the protocol. The 3 previously characterized strains, ATCC43504, 26695 and G27, 24 and the 10 H. pylori clinical isolates were cultured on Columbia blood agar plates (Difco, Detroit, MI, USA) containing 5% horse blood (Oxoid, Basingstoke, UK) in 10% CO 2 at 37 1C.
Determination of MIC
MIC was defined as the lowest concentration of MTZ that completely inhibited the growth of the inoculum. MICs were determined by the E-test method (AB Biodisk, Solna, Sweden) and agar dilution method. 25 The E-test was performed on Columbia blood agar plates containing 5% horse blood according to the manufacturer's instructions. The agar dilution method was performed on Columbia blood agar plates containing 5% horse blood as described earlier. 25 Frozen bacterial stocks were streaked on Columbia blood agar and incubated for 3 days. Cells from a few colonies from these initial plates were then restreaked on fresh Columbia blood agar plates and incubated for one more day. The resulting exponentially growing cells were suspended in phosphatebuffered saline; series of 10-fold dilutions of these cell suspensions were prepared, and 10 ml of each dilution was spotted on freshly prepared Columbia blood agar containing various concentrations (0, 0.2, 0.5, 1.5, 3, 5, 8, 16, 32, 64 or 256 mg ml À1 ) of MTZ (Sigma Chemical Co., St Louis, MO, USA). The plates were incubated for 3 days. MTZ-resistant H. pylori ATCC43504 and MTZsensitive 26695 were used as control strains. MTZ resistance was considered to be attained at an MIC of 48 mg ml À1 . 21 Cloning of rdxA and frxA genes of clinical H. pylori isolates Chromosomal bacterial DNA was extracted using the Wizard Genomic DNA purification kit (Promega, Madison, WI, USA). PCR amplifications of rdxA and frxA were carried out in a DNA thermal cycler (Biometra, Goettingen, Germany) using the Expand High Fidelity PCR System (Roche Applied Science, Mannheim, Germany) as follows: 1 cycle at 95 1C for 2 min; 30 cycles of 95 1C for 30 s, 55 1C for 30 s and 72 1C for 30 s and a final elongation step at 72 1C for 10 min. The oligonucleotide PCR primers used to amplify an 851-bp fragment containing the entire rdxA open reading frame were a forward primer (5¢-aatttgagcatggggcaga-3¢) and a reverse primer (5¢-gaaacgcttgaaaacacccct-3¢). Similarly, a forward primer (5¢-ccatcgatatggacagagaacaagtgg-3¢) and a reverse primer (5¢-gctaacagcgtttttattcaatc-3¢) were used to amplify the 675-bp fragment containing the entire frxA open reading frame. The amplified PCR fragments were extracted from 1% agarose gels using the QiaQuick Gel Extraction kit (Qiagen, Hilden, Germany), ligated into the pGEM-T-easy vector (Promega) and transformed into Escherichia coli DH5a, generating plasmid pRDXA-G27, -43504, -S1 to -S5 and -R1 to -R5, and pFRXA-G27, -43504, -S1 to -S5 and -R1 to -R5.
Nucleotide sequence analysis of rdxA and frxA of G27, ATCC43504 and clinically isolated H. pylori DNA sequences of rdxA and frxA of G27, ATCC43504 and the clinical isolates were determined for both strands of the inserts of pRDXA and pFRXA series (Cosmogenetech, Seoul, Republic of Korea) using T7 and SP6 primers. The resulting DNA sequences were analyzed by the vector NTI v9.1 (Invitrogen, Carlsbad, CA, USA) and Sequencher v4.5 (Gene Code, Ann Arbor, MI, USA) programs. The GenBank accession numbers for the sequences reported in this paper are EF444879-EF444880, EF471983-EF471992 and EF521388-EF521397.
Generation of rdxA constructs for natural transformation A 1.4-kb kanamycin (Km) resistance cassette (aphA-3) was PCR amplified from pILL600 26 using a forward primer (5¢-ccaagcttggcgtatcacgaggccctttcg-3¢) and a reverse primer (5¢-ccaagcttctaaaacaattcatccag-3¢), each containing a HindIII restriction enzyme site and two additional nucleotides. A unique HindIII restriction enzyme site in the rdxA fragment in pRDXA-S1 to -S5 and -R1 to -R5 was used to insert the Km resistance cassette. To avoid the leaky expression of rdxA due to readthrough from the expression of the Km resistance cassette, the Km resistance cassette was subcloned in the reverse direction to the rdxA gene. The direction was confirmed by sequencing the pRDXA series with the rdxA forward primer. The resulting plasmids carrying a Km resistance cassette were named pRDXA(Km) -S1 to -S5 and -R1 to -R5 and used for the rdxA replacement experiments.
Replacement of rdxA by natural transformation
The G27 H. pylori strain was used for replacement of the endogenous rdxA allele with the rdxA genes from the clinical isolates. Natural transformation with the pRDXA(Km) series was performed as described earlier 27 with the following modification: the G27 strain was struck and incubated for 3 days. Sweeps of G27 colonies from the initial plate were then restruck on a fresh Columbia blood agar plate and incubated. After 24 h, these cells were inoculated as a circle on a fresh Columbia blood agar plate with four 1-inch scrapes. After 6 h, 2 mg DNA of the pRDXA(Km) series was added to the G27 circle. After 20 h, the whole circle was restreaked onto Columbia blood agar containing Km (10 mg ml À1 ) and incubated for 3-5 days until transformants appeared.
PCR screening for the rdxA replacement of transformants
Integration of the pRDXA(Km) series in the rdxA locus of G27 H. pylori by single crossover homologous recombination was selected for by Km resistance (Figure 1 ). The rdxA replacement of the Km-resistant transformants was confirmed by PCR screening with the rdxA primers as described above and illustrated in Figure 1 . If the pRDXA(Km) series were integrated successfully into the wild-type rdxA locus, two bands of 851 bp (rdxA gene expressed by the endogenous rdxA promoter) and 2275 bp (promoterless rdxA gene containing the Km resistance cassette) should be observed. The small PCR band (851 bp) and large band (2275 bp) were extracted and sequenced (Cosmogene Tec.) with the rdxA primers and Km(seq) primer (5¢-cgaaagggcctcgtgatacg-3¢) to confirm the single crossover site of homologous recombination, the integration of rdxA of clinically isolated H. pylori and the interruption of G27 rdxA by the Km resistance cassette (Figure 1 ).
Reverse transcription-PCR
To confirm rdxA expression in the R3-R5 clinical H. pylori isolates, as well as expression of the integrated rdxA gene and lack of expression of the original G27 endogenous rdxA locus in H. pylori transformants, reverse transcription (RT)-PCR was performed on RNA from the R3-R5 clinical H. pylori isolates and H. pylori transformants, respectively. Total RNA was isolated using the RNeasy Protect Bacteria Mini kit (Qiagen) according to the manufacturer's instructions. Total RNA was treated with 1 U of RNase-free DNase I (Sigma Chemical Co.) for 15 min, which was then inactivated by adding 50 mM EDTA and heating to 70 1C for 10 min. Here, 1 mg of total RNA as a template and 10 pM of the rdxA(RT) reverse primer (5¢-gcattgctctaaaatatagc-3¢) were then used for cDNA synthesis using an RT kit (Bioneer, Daejeon, Republic of Korea) according to the manufacturer's instructions. PCR amplification of the rdxA cDNA was then carried out with the rdxA(RT) forward primer (5¢-ctatcgccaagctcttacaa-3¢) and reverse primer in a DNA thermal cycler (Biometra) using Maxime PCR PreMix (i-StarTaq) (iNtRON Biotechnology, Seongnam-Si, Republic of Korea) as follows: 1 cycle at 95 1C for 2 min; 35 cycles at 95 1C for 30 s, 48 1C for 30 s and 72 1C for 30 s and a final elongation step at 72 1C for 10 min. The final RT-PCR products (297 bp) were then run on an agarose gel to examine rdxA expression. For the negative control, total RNA of each sample was amplified by PCR without conducting a RT reaction. For these controls, no PCR products were observed, indicating no chromosomal DNA contamination.
To confirm the expression of only the integrated rdxA gene in the H. pylori transformants, the final RT-PCR products from the transformants were extracted and sequenced as described above.
RESULTS

Identification of MTZ-sensitive or -resistant clinical H. pylori isolates
As we wished to elucidate the specific contribution of rdxA and frxA to MTZ resistance in current clinical H. pylori isolates, the MICs of MTZ of several isolates from patients undergoing gastroscopy were first determined by both the E-test and the agar dilution method. For reference, the MTZ MICs were also determined for the well-studied Figure 1 Schematic representation of the integration of pRDXA(Km) in the rdxA locus of G27 chromosomal DNA by single crossover homologous recombination. In H. pylori, rdxA is transcribed as part of an operon with lgt. 25 The promoterless rdxA gene from individual clinical isolates (CIs) was amplified by PCR and a kanamycin resistance cassette was inserted into a unique HindIII restriction site within the context of the pRDXA(Km) integration vectors as described in Materials and methods. After transformation of G27 and selection for kanamycin resistance, transformants were screened by PCR to identify those where the pRDXA(Km) plasmid had integrated into the endogenous rdxA locus by homologous recombination. As illustrated in the bottom portion of the figure, two structural rdxA genes exist in the transformants, but only one of the genes can be expressed by the endogenous rdxA promoter and the other one is silent. Promoter elements are indicated by small arrows on the respective open reading frames. The relative position of the primers used to verify proper integration is indicated by the numbers 1 and 2 and the sizes of the indicated PCR products are indicated in base pairs. Items in the figure are not drawn to scale. 
Abbreviations: MIC, minimum inhibitory concentration; MTZ, metronidazole. a The amino acid is the same as that of the G27 strain. b A missense mutation resulted in the amino-acid substitution. c A nonsense mutation resulted in the stop codon at residue 50. d A frame-shift mutation resulted in the stop codon at residue 153.
H. pylori strains G27, ATCC43504 and 26695 (Tables 1 and 2 ). As expected, G27 and 26695 were sensitive to MTZ (MIC, 0.75 mg ml À1 ), whereas ATCC43504 was resistant (MIC, X256 mg ml À1 ). Five isolates (S1-S5) that were sensitive to MTZ (MIC, 0.38, 0.25, 0.13, 0.19 and 0.25 mg ml À1 , respectively) and five isolates (R1-R5) that were resistant to MTZ (MIC, 64, 128 and R3-R5 X256 mg ml À1 , respectively) were selected for further in-depth analysis (Table 1) .
Amino-acid sequences of RdxA and FrxA from MTZ-sensitive and -resistant H. pylori isolates To identify putative MTZ resistance-associated mutations in rdxA and frxA, both genes were sequenced from the 10 H. pylori clinical isolates, as well as from the G27 and ATCC43504 reference strains. The DNA sequences obtained for rdxA and frxA from ATCC43504 were identical to the sequences reported earlier. 4, 28 Moreover, the deduced aminoacid sequence of RdxA and FrxA from the DNA sequence of ATCC43504 indicates that this strain produces truncated non-functional forms of both proteins. The deduced RdxA amino-acid sequences of G27 and the 10 clinical isolates were compared to identify any potential resistanceassociated nucleotide mutations ( Table 1 ). All of the six MTZ-sensitive strains (G27 and the five clinical isolates) encode full-length RdxA, but each clinical isolate contains 5-8 amino-acid substitutions arising as a result of missense mutations ( Table 1) . As these strains are all MTZ-sensitive, these amino-acid changes are probably not important for nitroreductase function and hence MTZ resistance. Instead, these variations are likely a by-product of the natural genetic diversity of H. pylori, which, in the case of rdxA, is estimated to be 5-8%. 29, 30 Two of five MTZ-resistant H. pylori isolates (R1 and R2) contained truncated RdxAs due to a nonsense mutation at amino acid 50 and a frameshift resulting in termination at residue 153, respectively. The amino-acid sequence of three (R3-R5) of the MTZ-resistant isolates identified full-length RdxA containing 6-9 amino-acid substitutions.
Comparison of the amino-acid sequence between the MTZ-sensitive and -resistant H. pylori isolates suggests that substitutions of asparagine at residue 64 and asparagine at residue 98 in the R3 strain, and substitutions of valine at residue 26 and proline at residue 40 in the R5 strain might be important for MTZ resistance. The amino-acid sequence of R4 was virtually identical to that of S5 except for a predicted neutral mutation (Met to Ala) at residue 21 in S5, suggesting that the R4 RdxA is functional similar to the S5 RdxA.
As FrxA has been suggested to play a role in MTZ resistance, we next analyzed the deduced FrxA amino-acid sequences to identify any amino-acid changes. As FrxA is truncated in G27, the FrxA aminoacid sequence from 26695 was used to compare the FrxA sequence of the 10 clinical isolates ( Table 2 ). All five of the MTZ-sensitive H. pylori strains encoded full-length FrxA containing 5-12 amino-acid substitutions by missense mutations. Among the five MTZ-resistant H. pylori isolates, R4 encodes a truncated FrxA due to a nonsense mutation at residue 68. The amino-acid sequences of the four remaining MTZ-resistant isolates (R1, R2, R3 and R5) showed fulllength FrxA containing 10-12 amino-acid substitutions by missense mutations. Surprisingly, no putative MTZ resistance-associated missense mutations of frxA were identified as no unique missense mutation in the MTZ-resistant strains was identified, as compared with the MTZ-sensitive strains. The one exception was a neutral mutation (Ala to Val) at residue 152 or 153. It is noted that the FrxA sequence from G27 showed that this MTZ-sensitive strain, which encodes a full-length RdxA protein, contained a truncated FrxA due to a frameshift mutation at residue 21. This strongly suggests that truncation of frxA alone does not result in MTZ resistance. Given that mutation of frxA was not sufficient to impart MTZ resistance, we focused the remainder of our studies on the role of rdxA mutations on MTZ resistance.
Analysis of clinical rdxA alleles in an isogenic H. pylori background To directly evaluate the contribution of the truncated rdxA and substituted rdxA alleles to MTZ resistance in an isogenic strain background, the rdxA locus of MTZ-sensitive wild-type H. pylori was genetically replaced with the rdxA gene of several of the clinical isolates (Figure 1 ). G27 was chosen as the recipient for the rdxA replacement because G27 is MTZ sensitive (MIC, 0.75 mg ml À1 ), is capable of natural transformation and encodes a truncated FrxA protein. We considered the truncation of FrxA to be important as an earlier study suggested that combined inactivation of FrxA and RdxA enhances MTZ resistance. 21 The rdxA gene from S4, S5 and R1-R5 were introduced into G27 by natural transformation with pRDXA(km)-S4, -S5 and -R1-R5 ( Figure 1 ). The S4 and S5 rdxA alleles were selected as representative forms of rdxA from the MTZsensitive strains. The pRDXA(km) plasmid series does not replicate in H. pylori, and thus to obtain the Km resistance phenotype, the plasmid must integrate into the rdxA chromosomal locus by single crossover homologous recombination (Figure 1 ). Thus, after transformation a merodiploid is produced where only the introduced rdxA is expressed by the endogenous rdxA promoter. To avoid the leaky expression of rdxA from the Km resistance cassette promoter, the Km resistance cassette was subcloned in the reverse orientation to the rdxA gene ( Figure 1 ). The proper rdxA replacement in the Km-resistant transformants was confirmed by PCR with the rdxA primer set that showed the following two bands; an 851-bp band (rdxA gene expressed from the endogenous promoter) and a 2275-bp band (a promoterless rdxA containing the Km resistance cassette) (Figures 1 and 2) . In addition to the PCR analysis, the expressing rdxA gene (small PCR product) was sequenced to confirm the single crossover site and the complete replacement with the clinical isolates rdxA locus (data not shown). Finally, interruption of the native G27 rdxA gene by the Km resistance cassette was confirmed by sequencing of the large PCR product (2275 bp) (data not shown). For all natural transformations, we isolated transformants in which the single crossover occurred upstream from the first identified amino-acid change. Therefore, the clinical isolates rdxA allele completely replaced the G27 rdxA gene. At least three individual transformants from each complete replacement were obtained and analyzed further.
Verification of expression of the introduced rdxA gene but not the G27 endogenous rdxA To confirm that the rdxA expressed by each of our merodiploid strains was indeed from the integrated copy of rdxA from our clinical isolates, we performed RT-PCR for the rdxA locus using total RNA harvested from the H. pylori transformants. On the basis of the assumption that the sequence of the cDNA produced from these RT reactions would show whether the integrated rdxA or endogenous rdxA was being expressed, we compared these cDNA sequences to the sequences we obtained earlier (Table 1) . Total RNA from each sample was also amplified by PCR without first conducting a RT reaction and no PCR products were observed, indicating that there was no chromosomal DNA contamination (data not shown).
The RT-PCR products of R1-R5 were each extracted from an agarose gel and sequenced. The sequence analysis indicated that each H. pylori transformant indeed expressed only the integrated rdxA from the clinical H. pylori isolates as the expression of the disrupted original G27 rdxA could not be detected.
MIC determination of rdxA-replaced H. pylori transformants To determine whether the MTZ resistance/sensitivity profile of the clinical isolates was transferred by the expression of the clinical rdxA locus in the isogenic strain background, the MTZ MICs of the rdxAreplaced H. pylori transformants were determined by both the E-test and agar dilution method. As shown in Table 3 , replacement with the rdxA genes from the MTZ-sensitive strains (S4 and S5) resulted in H. pylori transformants that remained sensitive to MTZ (MIC, 0.75 and 0.35 mg ml À1 , respectively). This was expected as the RdxAs of the MTZ-sensitive strains should be functional. The MICs were similar to that of the recipient strain, G27 (MIC, 0.75 mg ml À1 ). Replacement with the rdxA genes from the MTZ-resistant strains (R1-R5) resulted in a wide range of MICs (0.25-X256 mg ml À1 ). As expected, replacement with rdxA from R1 and R2 resulted in high resistance to MTZ (MIC, X256 mg ml À1 ). These results indicate that truncated, and hence non-functional, RdxA causes MTZ resistance in H. pylori. In addition, the MICs were higher than those of the original clinical isolated H. pylori strains (R1 MIC, 64 mg ml À1 and R2 MIC, 128 mg ml À1 ). This is in keeping with the idea that the truncated FrxA already found in G27 can enhance MTZ resistance in the presence of a non-functional rdxA mutation. Unexpectedly, replacement with the rdxA genes from the MTZ-resistant strains R3, R4 and R5 still resulted in sensitivity to MTZ (MIC, 0.25-0.75, 0.25-3 and 0.25-3 mg ml À1 , respectively). We originally predicted that the asparagine substitution at residue 64 and asparagine at residue 98 in the R3 strain, and the valine at residue 26 and proline at residue 40 in the R5 might be important for MTZ resistance (Table 1) . However, the fact that the rdxA replacement containing these amino acids still resulted 
Abbreviations: MIC, minimum inhibitory concentration; MTZ, metronidazole. The rdxA replacement of MTZ-sensitive G27 (MIC, 0.75 mg ml À1 ) with the rdxAs of the clinical isolates resulted in the following MTZ MICs. in MTZ sensitivity suggests that these substitutions are not significant for MTZ resistance and thus reductase function.
Verification of rdxA expression in the clinical isolates As we examined expression of the clinical rdxA allele in G27 using the G27 promoter to drive expression of the transferred rdxA gene, we sought to ensure that the R3-R5 clinical isolates did not contain any promoter mutations that prevented rdxA expression in the context of the clinical strain background. Therefore, rdxA expression was examined by RT-PCR in the R3-R5 clinical isolates as well as in G27. This analysis showed that each of the strains expressed rdxA (Figure 3) . Therefore, any variations in the upstream sequences in R3-R5 do not prevent rdxA expression and thus, do not explain the obtained MTZ resistance profiles of the clinical isolates. Finally, as R3-R5 apparently encode functional RdxA and as mutations upstream of the RdxA start codon have been identified that affect MTZ resistance, 21 we investigated whether there were any nucleotide mutations in this region that might affect RdxA translation in the original R3-R5 clinical isolates. To examine sequence polymorphisms, the region upstream of the ATG start codon, which includes the Shine-Dalgarno sequence of rdxA, were sequenced in all 10 clinical isolates ( Table 4) . The sequences were then compared with that of HP2600 28 and G27, which are both sensitive to MTZ. As all the clinical isolates showed sequences that were most similar to HP2600, we focused our comparison to this MTZ-sensitive strain. Because the sequences of S2-S5 and R3 and R4 were the same as that of HP2600 there are no changes that can account for the MTZ resistance seen in R3 and R4. In addition, the sequences of S1 and R2 were identical, suggesting that the single nucleotide difference from the HP2600 sequence is not important for MTZ resistance. The sequence of R1 and R5 showed a one nucleotide (G) deletion, which might affect rdxA expression; however, the sequence of G27 has four nucleotide variations in this same region. As G27 is sensitive to MTZ, it seems unlikely that these variations should affect rdxA expression in R1 and R5.
DISCUSSION
This study examined the resistance of H. pylori to the anti-microbial agent MTZ and specifically focused on the contribution of the rdxA and frxA genes to MTZ resistance. Five MTZ-sensitive and five MTZresistant H. pylori strains were obtained from the clinical isolates. Analysis of the deduced RdxA and FrxA amino-acid sequences of these isolates revealed various mutations. To directly evaluate the contribution of these specific rdxA mutations to MTZ resistance, we introduced these rdxA variants into G27 while inactivating its own rdxA gene. Our results show that (i) premature truncation of frxA alone is not sufficient to cause MTZ resistance in H. pylori, but has the capacity to enhance MTZ resistance in H. pylori containing a deficient rdxA; (ii) introduction of an inactivated rdxA (non-functional premature truncation) is sufficient to confer MTZ resistance to G27 (normally MTZ sensitive); (iii) introduction of the missense-mutated rdxA alleles (6-9 amino-acid substitutions each) does not result in MTZ resistance; (iv) three high MTZ-resistant isolates (MIC, X256 mg ml À1 ) have functional rdxA, suggesting that an MTZ resistance phenotype can arise in H. pylori in the absence of inactivating mutations in rdxA.
MTZ resistance associated with mutation of frxA is still one of the most controversial topics. Kwon et al. 22 reported that frxA inactivation resulted in MICs (32 or 128 mg ml À1 ) similar to those seen with rdxA inactivation, whereas a study by Jeong et al. 21 showed that frxA inactivation enhanced MTZ resistance in rdxA-deficient H. pylori but had little effect on the MTZ susceptibility of strains carrying a functional rdxA allele. In addition, Yang et al. 23 recently identified the truncation of FrxA in an MTZ-sensitive H. pylori isolate. Our results agree with the studies of the Jeong and Yang groups. MTZ-sensitive G27 (MIC, 0.75 mg ml À1 ) contains a truncated FrxA due to a frameshift-causing termination at residue 21. As full-length FrxA is 217 amino acids, the truncated FrxA is most likely non-functional. Therefore, the functional inactivation of FrxA alone cannot induce MTZ resistance in this strain. In addition, the comparison of FrxA aminoacid sequences (Table 2) shows that none of the putative missense mutations is likely to be responsible for MTZ resistance as no unique missense mutations in the MTZ-resistant strains were identified with the exception of a neutral mutation (Ala to Val) at residue 152 or 153. It is worth noting that the replacement of G27 rdxA with the nonsense-mutated rdxA (premature truncation) from R1 (MIC, 64 mg ml À1 ) and the frameshift-mutated rdxA (premature truncation) (Table 2 ). This fact suggests that FrxA inactivation does indeed enhance MTZ resistance in rdxA-deficient H. pylori and is in agreement with the study of Jeong et al. 21 Several rdxA replacements were performed to evaluate the role of rdxA mutations in MTZ resistance. We designed our study such that the replaced rdxAs of all transformants were expressed by the same G27 endogenous rdxA promoter. This design enabled us to avoid the potential problem of differential promoter regulation and as a result, all transformants are in the same genetic background. Earlier, presumably important mutations of rdxA for MTZ resistance were simply identified by comparison of the RdxA sequence between MTZsensitive and -resistant H. pylori strains. 2, 31, 32 However, these mutations were not evaluated directly for their contribution to MTZ resistance. Comparative analysis of the RdxA sequences in our study predicted that the changes of Lys64-Asn and Gly98-Asn in the R3 strain, and Tyr26-Val and Ala40-Pro in the R5 strain might be responsible for MTZ resistance. rdxA replacement proved that these substitutions are not critical changes in MTZ resistance as the G27 strain carrying them remained MTZ sensitive. These findings suggest that the amino-acid changes should be attributed to natural genetic diversity and are not associated with MTZ resistance. Recent studies revealed the RdxA amino-acid changes of Arg10-Lys, Arg16-His, Met21-Ala, His53-Arg, Met56-Ile, Leu62-Val, Ala68-Val, Gly98-Ser, Gly163-Asp and Ala206-Thr in MTZ-resistant strains, 2, 31, 32 suggesting that those substitutions may be important in MTZ resistance. However, in our study the replacement with the missense-mutated rdxA containing amino-acid substitutions (Met21-Ala, Leu62-Val, Gly98-Ser and Ala206-Thr) failed to transfer the MTZ-resistant phenotype, suggesting that the substitutions are not important for MTZ resistance. In addition, only Paul et al. 32 confirmed experimentally that RdxA amino-acid substitutions (Cys19-Tyr and Thr49-Lys) were causative for MTZ resistance. In that study, MTZ-sensitive strains were transformed with PCR products of MTZ-resistant rdxA and the appearance of MTZ-resistant isolates was selected for studies on MTZ. MTZ-resistant transformants were then analyzed for their rdxA sequences. It should be noted that it is formally possible that the selective pressure of MTZ applied in that study forced other mutations to arise elsewhere that result in MTZ resistance. The PCR-transformed strains were not screened for putative resistance-associated mutations in other genes. To prevent MTZselective pressure in our study, the transformants were selected by Km resistance and MTZ MICs were then measured. In the future, it will be interesting to directly assess the role of the RdxA substitutions identified by Paul et al. 32 for their significance in MTZ resistance using the rdxA replacement strategy.
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R5 G C T A C -A A A A A T T C T A A A A A A A T A A A G G A A A A T C A A T G
Three clinical isolates (R3-R5) showed high resistance to MTZ (MIC, X256 mg ml À1 ), even though our data indicate that they have functional rdxA. This result is in agreement with Marais et al. 33 who suggested that an MTZ resistance phenotype may arise in H. pylori without mutation in rdxA or frxA. Interestingly, several groups 22, [34] [35] [36] [37] and genome sequence annotation [38] [39] [40] suggest other putative redox systems that may play a role in MTZ resistance. These include fdxB (encoding a ferredoxin-like protein), fdxA (ferredoxin), fldA (flavodoxin), oorD (the g-subunit of 2-oxoglutarate oxidoreductase and porD (the g-subunit of pyruvate ferredoxin oxidoreductase). However, with the exception of fdxB, research to identify other MTZ important redox systems has been hampered because the deletion of the genes seems to be lethal for H. pylori. 22 Recently, van Amsterdam et al. 41 reported that double mutation of HP0605 and HP0971 (TolC-like proteins) results in decreased MTZ resistance (from wild-type MIC, 4256 mg ml À1 to 8 mg ml À1 ), indicating that the TolC efflux pump may confer resistance to MTZ. Therefore, H. pylori possessing TolC efflux pumps may be resistant to MTZ independent of rdxA or frxA mutations.
In summary, the findings of this study clarify some of the debate surrounding the questions of whether deletion of frxA alone can induce MTZ resistance or simply enhance the resistance in an rdxAdeficient H. pylori strain. Additionally, our rdxA replacement approach provides some of the first analysis of the role of specific mutations in MTZ resistance. Our results show that deletion of rdxA induces MTZ resistance, but that none of the 15 amino-acid substitutions found in rdxA of the MTZ-resistant strains is able to cause MTZ resistance. This strongly suggests that the substitution mutations identified previously by sequence comparison need to be directly analyzed for their contribution to MTZ resistance. Finally, MTZ resistance in H. pylori can arise without mutations in rdxA or frxA, clearly suggesting that other genetic elements are involved in MTZ resistance. Future work from our group will focus on the identification of the genes responsible for this MTZ resistance phenotype.
